Journal: Nat Commun / Year: 2024 Title: Tumor-agnostic cancer therapy using antibodies targeting oncofetal chondroitin sulfate. Authors: Elena Ethel Vidal-Calvo / Anne Martin-Salazar / Swati Choudhary / Robert Dagil / Sai Sundar Rajan Raghavan / Lara Duvnjak / Mie Anemone Nordmaj / Thomas Mandel Clausen / Ann Skafte / Jan ...Authors: Elena Ethel Vidal-Calvo / Anne Martin-Salazar / Swati Choudhary / Robert Dagil / Sai Sundar Rajan Raghavan / Lara Duvnjak / Mie Anemone Nordmaj / Thomas Mandel Clausen / Ann Skafte / Jan Oberkofler / Kaituo Wang / Mette Ø Agerbæk / Caroline Løppke / Amalie Mundt Jørgensen / Daria Ropac / Joana Mujollari / Shona Willis / Agnès Garcias López / Rebecca Louise Miller / Richard Torbjörn Gustav Karlsson / Felix Goerdeler / Yen-Hsi Chen / Ana R Colaço / Yong Wang / Thomas Lavstsen / Agnieszka Martowicz / Irina Nelepcu / Mona Marzban / Htoo Zarni Oo / Maj Sofie Ørum-Madsen / Yuzhuo Wang / Morten A Nielsen / Henrik Clausen / Michael Wierer / Dominik Wolf / Ismail Gögenur / Thor G Theander / Nader Al-Nakouzi / Tobias Gustavsson / Mads Daugaard / Ali Salanti / Abstract: Molecular similarities between embryonic and malignant cells can be exploited to target tumors through specific signatures absent in healthy adult tissues. One such embryonic signature tumors express ...Molecular similarities between embryonic and malignant cells can be exploited to target tumors through specific signatures absent in healthy adult tissues. One such embryonic signature tumors express is oncofetal chondroitin sulfate (ofCS), which supports disease progression and dissemination in cancer. Here, we report the identification and characterization of phage display-derived antibody fragments recognizing two distinct ofCS epitopes. These antibody fragments show binding affinity to ofCS in the low nanomolar range across a broad selection of solid tumor types in vitro and in vivo with minimal binding to normal, inflamed, or benign tumor tissues. Anti-ofCS antibody drug conjugates and bispecific immune cell engagers based on these targeting moieties disrupt tumor progression in animal models of human and murine cancers. Thus, anti-ofCS antibody fragments hold promise for the development of broadly effective therapeutic and diagnostic applications targeting human malignancies.
In the structure databanks used in Yorodumi, some data are registered as the other names, "COVID-19 virus" and "2019-nCoV". Here are the details of the virus and the list of structure data.
Jan 31, 2019. EMDB accession codes are about to change! (news from PDBe EMDB page)
EMDB accession codes are about to change! (news from PDBe EMDB page)
The allocation of 4 digits for EMDB accession codes will soon come to an end. Whilst these codes will remain in use, new EMDB accession codes will include an additional digit and will expand incrementally as the available range of codes is exhausted. The current 4-digit format prefixed with “EMD-” (i.e. EMD-XXXX) will advance to a 5-digit format (i.e. EMD-XXXXX), and so on. It is currently estimated that the 4-digit codes will be depleted around Spring 2019, at which point the 5-digit format will come into force.
The EM Navigator/Yorodumi systems omit the EMD- prefix.
Related info.:Q: What is EMD? / ID/Accession-code notation in Yorodumi/EM Navigator
Yorodumi is a browser for structure data from EMDB, PDB, SASBDB, etc.
This page is also the successor to EM Navigator detail page, and also detail information page/front-end page for Omokage search.
The word "yorodu" (or yorozu) is an old Japanese word meaning "ten thousand". "mi" (miru) is to see.
Related info.:EMDB / PDB / SASBDB / Comparison of 3 databanks / Yorodumi Search / Aug 31, 2016. New EM Navigator & Yorodumi / Yorodumi Papers / Jmol/JSmol / Function and homology information / Changes in new EM Navigator and Yorodumi